Pharmaceutical titan Novo Nordisk rakes in record £4.5BILLION due to success of its game-changing weight loss jabs Ozempic and Wegovy

Danish pharmaceutical titan Novo Nordisk raked in £4.5billion during the first half of 2023 – up by a third, or £1.3billion, on the previous spell. Bosses credited demand for its weekly semaglutide jabs.Danish pharmaceutical titan Novo Nordisk raked in £4.5billion during the first half of 2023 – up by a third, or £1.3billion, on the previous spell. Bosses credited demand for its weekly semaglutide jabs.Read MoreHealth News | Mail Online